Kedrion Biopharma expands to North America with Prometic acquisition

By Nikita Chaurasia  | Date: 2021-10-19

Kedrion Biopharma expands to North America with Prometic acquisition
  • Prometic Life Sciences has developed the first FDA-approved treatment for Congenital Plasminogen Deficiency.
  • This acquisition will enable easy access to advanced therapies for patients suffering from this rare disease.

Kedrion Biopharma Inc. has reportedly acquired Canada-based biopharmaceutical company Liminal BioSciences Inc. previously known as Prometic Life Sciences, as a part of the plans to expand its reach in North America.

The company is also working towards a launch in the United States in 2022, cited sources with reliable information.

For the record, Liminal BioSciences Inc. employs 130 people in Quebec and has developed the first FDA-certified treatment option for Congenital Plasminogen Deficiency. The new drug, named Ryplazim, can be used to treat Plasminogen Deficiency which can cause respiratory failure, blindness, and other chronic complications.

Chairperson of Kedrion Biopharma, Paolo Marcucci was quoted saying that the acquisition will ensure that patients suffering from this rare disease have easy access to treatment. He also claimed that the deal is a part of the company’s strategy to expand its reach in North America – a region from which the company derives nearly 50% of its revenues.

With the acquisition, Kedrion Biopharma has completed a series of transactions which the company started in June 2020, including the purchase of Liminal’s plasma purification plant at Laval in Quebec, and the license to distribute Ryplazim in the United States.

Chief Executive Officer of Kedrion Biopharma, Val Romberg reportedly said that the development & distribution of Ryplazim allows the company to fulfill the mission of putting patients first. This is the first FDA-approved drug for Type 1 Congenital Plasminogen Deficiency, and the company is honored to help speed its distribution in the market, he added.

In addition to the Quebec plant, Kedrion Biopharma also acquired two new plasma collection centers located in Winnipeg, Manitoba, and Amherst, New York as a part of this agreement.

Source Credits—

https://www.prnewswire.com/news-releases/kedrion-biopharama-grows-in-north-america-as-it-completes-acquisition-of-prometic-301401799.html

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More >>

More News By Nikita Chaurasia

L&T Technology Services partners with Qualcomm to amplify 5G adoption

L&T Technology Services partners with Qualcomm to amplify 5G adoption

By Nikita Chaurasia

L&T Technology Services Limited has recently announced that it is teaming up with Qualcomm Technologies, Inc., the world’s leading wireless technology innovator. With the latest collaboration, the firm plans to offer end-to-end solutions...

PNAS, Straive partner to deliver end-to-end content production services

PNAS, Straive partner to deliver end-to-end content production services

By Nikita Chaurasia

Renowned U.S.-based nonprofit and non-governmental organization, NAS (National Academy of Sciences), has reportedly collaborated with Straive, one of the leading technology-driven solutions providers for Content, EdTech, and Data. With this acquis...

Japan pushes innovations in 'deep tech' sector with solar cell technology

Japan pushes innovations in 'deep tech' sector with solar cell technology

By Nikita Chaurasia

Amid the most promising next-generation solar cell technology innovations, Enecoat Technologies, a provider of materials development services in Japan, is reportedly developing perovskite. Following its completion, the Kyoto-located start-up expec...

GIC to acquire majority shares in opulent Sani/Ikos properties

GIC to acquire majority shares in opulent Sani/Ikos properties

By Nikita Chaurasia

Singapore's sovereign wealth fund, GIC has agreed to pay around $2.2 billion to buy a majority stake in Sani/Ikos Group, a Mediterranean luxury resort operator, marking the largest transaction in the European resort market since the Covid-19 pand...

Excelra, Patcore partner to offer enhanced digital insights to customers

Excelra, Patcore partner to offer enhanced digital insights to customers

By Nikita Chaurasia

Excelra, a data and analytics solutions provider, has recently announced its partnership with Patcore, Inc., to provide better access to its analytics products and scientific data for customers in Japan. For the unversed, Excelra is one of the top...